Clinical Trials Logo

Bladder, Overactive clinical trials

View clinical trials related to Bladder, Overactive.

Filter by:
  • None
  • Page 1

NCT ID: NCT05463822 Completed - Overactive Bladder Clinical Trials

Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder

FETOC
Start date: June 20, 2019
Phase: Early Phase 1
Study type: Interventional

Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into the detrusor muscle of the bladder. However, the traditional procedure requires a cystoscope inserted into the bladder which can be painful and is associated with a risk of urinary tract infection. The purpose of this study is to determine if transvaginal injection of BTA into the detrusor muscle of the bladder wall is feasible to perform, and efficacious for the treatment of refractory overactive bladder.

NCT ID: NCT05106504 Recruiting - Parkinson Disease Clinical Trials

Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease

Start date: September 2, 2021
Phase:
Study type: Observational

Medical cannabis (MC) is a standard treatment in Israel to Parkinson's disease (PD) patients suffering from pain. Nevertheless, it is not known about MC effectiveness for other non-motor symptoms of the disease. Our aim is to prospectively observe patients with PD before and after initiation of MC, for non-motor symptoms effect. In specific, relying of data from multiple sclerosis patients and basic science showing cannabinoid receptor 1 (CB1) is abundantly expressed in the sub epithelial layer of the bladder, we will explore the impact of MC on bladder function and urinary symptoms.

NCT ID: NCT04160793 Not yet recruiting - Bladder, Overactive Clinical Trials

Genital Nerve Stimulation - GNS - for Treatment of Non-neurogenic OAB

GNS
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The Genital Nerve Stimulation - GNS - consists of a two-step procedure with a preoperative non-surgical test-phase and a final surgical implantation of the neuroprothesis. In contrast to the classical technique of transcutaneous lead electrode implantation for sacral or pudendal nerve stimulation, the GNS-test-phase does not require any interventional procedure: because the genital nerves are located just few millimeter below the skin, test-stimulation can be achieved using skin surface or needle electrodes. Stimulation is achieved using a battery powered hand-held stimulator . The effect of the stimulation can be tested by the patient in their daily, home and professional environment, or at the practice under urodynamic testing, or if required other electrophysio-logical testing. After confirmation of the effectiveness of GNS, implantation of a permanent neuroprothesis can be planned. The procedure is performed either under general or spinal anesthesia or using only local anesthesia with IV-sedation as in the classical tension-free vaginal tape procedure (TVT). Because the GNS does not require two surgical procedures for both the test- and the final-implantation but rather only one for the final implantation, the presented protocol allows considerable cost reduction in comparison to the usual procedures for sacral or pudendal nerve stimulation.

NCT ID: NCT04075578 Recruiting - Bladder, Overactive Clinical Trials

Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)

TOX50IUU
Start date: June 26, 2019
Phase:
Study type: Observational

Considering that the 2013 Hermieu's guidelines differs from the product marketing authorization delivered in November 2014, the primary endpoints is to evaluate life quality by questionnaires at the baseline time, and after two, six and twelve weeks of treatment in patients suffer from urinary incontinence by refractory idiopathic overactive bladder and treated by Botox® at the dose of 50UI (international units)

NCT ID: NCT03238053 Not yet recruiting - Breast Cancer Clinical Trials

Laser Treatment of Genito-urinary Syndrome in Women

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Women with genitourinary syndrome of menopause, overactive bladder, with breast or endometrial cancer are randomized to either laser treatment og sham treatment for 3 months. The randomization is stratified for estrogen treatment. The effect is evaluated by questionnaire, histology and microbiology swaps